Literature DB >> 11173644

Molecular Events as Targets of Anticancer Drug Therapy.

Adorján Aszalós1, Sándor Eckhardt.   

Abstract

The aim of this review is to introduce some molecular targets for cancer chemotherapy, with comments on their mode of action, preclinical and clinical results. The representatives of the following groups are covered: phosphorylation inhibitors, protein kinase modulators, receptor antagonists, immunomodulators, differentiating agents, multidrug resistance modulation, telomerase inhibitors, and bioreductive agents.

Entities:  

Year:  1997        PMID: 11173644     DOI: 10.1007/bf02907812

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  102 in total

1.  Signal transduction: crosstalk.

Authors: 
Journal:  Trends Biochem Sci       Date:  1992-10       Impact factor: 13.807

Review 2.  The bryostatins.

Authors:  G R Pettit
Journal:  Fortschr Chem Org Naturst       Date:  1991

Review 3.  Clinical trials of P-glycoprotein reversal in solid tumours.

Authors:  D R Ferry; H Traunecker; D J Kerr
Journal:  Eur J Cancer       Date:  1996-06       Impact factor: 9.162

Review 4.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  The protein kinase C activator Bryostatin-1 induces the rapid release of TNF alpha from MONO-MAC-6 cells.

Authors:  K G Steube; H G Drexler
Journal:  Biochem Biophys Res Commun       Date:  1995-09-25       Impact factor: 3.575

Review 6.  Clinical trials of agents that reverse multidrug resistance. A literature review.

Authors:  M Raderer; W Scheithauer
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

Review 7.  Regulation of multidrug resistance through the cAMP and EGF signalling pathways.

Authors:  C Rohlff; R I Glazer
Journal:  Cell Signal       Date:  1995-07       Impact factor: 4.315

8.  Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture.

Authors:  W B Malarkey; M Kennedy; L E Allred; G Milo
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

9.  Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

10.  Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL.

Authors:  Z Han; D Chatterjee; J Early; P Pantazis; E A Hendrickson; J H Wyche
Journal:  Cancer Res       Date:  1996-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.